Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage III bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 55 for your search:
Start Over
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection [IMvigor010]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29636, NCI-2015-01334, 2014-005603-25, NCT02450331
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991001, NCI-2016-00304, 2015-003262-86, JAVELIN Bladder 100, NCT02603432
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: WO30070, NCI-2016-00967, 2016-000250-35, NCT02807636
Polypropylene Mesh in Preventing a Parastomal Hernia in Patients with Non-metastatic Bladder Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: Any age
Trial IDs: 16-1285, NCI-2016-01489, NCT02908061
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-020, NCI-2014-00315, 2014-002605-38, NCT01968109
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: B-701-U21, NCI-2015-00701, NCT02401542
Ixazomib Citrate with Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients with Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0661, NCI-2015-00682, NCT02420847
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GEN702, NCI-2015-01770, NCT02552121
Radiation Therapy in Preventing Brain Metastases in Patients with Locally Advanced or Metastatic Bladder or Urinary Tract Cancer Previously Treated with Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2007-0933, NCI-2012-01675, NCT00756639
Gemcitabine Hydrochloride and Cisplatin in Treating Patients with High-Grade Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-208, NCI-2010-02376, NCT01261728
3D Conformal Radiation Therapy after Surgery in Treating Patients with High-Risk Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RAD2271-12, NCI-2013-01381, IRB00059097, NCT01954173
Gene Expression Profiling in Predicting Chemotherapy Response in Patients with Localized, Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1314, NCI-2014-00850, NCT02177695
An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR105065, NCI-2015-00818, 2014-002408-26, 42756493BLC2001, NCT02365597
Regorafenib in Treating Patients with Advanced Urothelial Cancer After Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 19 and over
Trial IDs: UAB1477, NCI-2015-01824, NCT02459119
Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-126, NCI-2015-01786, NCT02553642
Nanoparticle Albumin-Bound Rapamycin in Treating Patients with Advanced Cancer with mTOR Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1313, NCI-2015-02151, NCT02646319
Pembrolizumab, Gemcitabine Hydrochloride and Radiation Therapy in Treating Patients with Bladder Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S15-00220, NCI-2016-00717, NCT02621151
Gemcitabine Hydrochloride, Cisplatin, and Pembrolizumab before Surgery in Treating Patients with Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC1520, NCI-2016-00790, NCT02690558
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Atezolizumab, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with Metastatic and Muscle Invasive Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-1428, NCI-2017-00228, NCT02989584
Start Over